Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents

Abstract

Treatment of neovascular age-related macular degeneration (nAMD) has been transformed by intraocular injection of therapies that inhibit vascular endothelial growth factor (VEGF).¹ The goal of therapy is to achieve a macula free of exudation.² Clinicians use optical coherence tomography (OCT) criteria (indicating disease activity) to tailor retreatment.³ Although it is critically important to optimize the treatment regimen to achieve the best possible outcome, there is also a desire to achieve this goal with the fewest treatments and patient visits.⁴ However, after initial control of active disease has been achieved, recurrence of fluid does not appear to have a clinically important adverse effect on functional outcome if managed with prompt retreatment.^5-7